Clinical Trials
14 trialsNCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT07262619 2026-04-08
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Eikon Therapeutics
Phase 1/2 Recruiting
NCT05838768 2026-03-24
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Novartis
Phase 1 Active not recruiting
NCT07213609 2026-03-23
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
Phase 1/2 Recruiting
NCT06305962 2026-02-19
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Radiopharm Theranostics, Ltd
Phase EARLY_PHASE1 Recruiting
NCT03767348 2026-02-13
IGNYTE
Replimune, Inc.
Phase 2 Active not recruiting
NCT06710847 2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03894618 2025-04-02
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
Phase 1 Completed
NCT05909995 2025-02-18
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT06034860 2024-11-01
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
Phase 1 Terminated
NCT03053466 2022-05-09
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Apollomics (Australia) Pty. Ltd.
Phase 1 Completed
NCT03652077 2021-11-15
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed